Lifeboat Foundation

josefkubes/Shutterstock

Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.

San Diego-based Cidara Therapeutics will receive an upfront payment of $27 million from Janssen, a division of J&J for the development of CD388, one of Cidara’s Cloudbreak antiviral conjugates (AVCs). Cidara, which is focusing on the development of therapeutics for serious fungal or viral infections, said CD388 has the potential to be a true universal preventative for the flu, with distinct advantages over vaccines that can be used across all populations, including the young, elderly and immunocompromised. Additionally, the company believed CD388 is capable of providing protection from all influenza strains, including seasonal and pandemic influenza A, influenza B and all major clinically characterized drug resistant influenza strains. Not only that, but Cidara suggests CD388 could provide a therapeutic role, such as the widely-used Tamiflu.

Circa 2014 o.o!

A new design for a piston-free linear engine generator has just been released by Toyota. With remarkable efficiency, the device might be scaled up to compete with electric power plants used in cars today.

Continue reading “Toyota develops high-efficiency ‘free piston’ no-crankshaft combustion engine… to power an EV” »

Deepfakes from above.

Deepfakes are usually associated with imagery of AI-generated people, but what about fake satellite imagery? Geographers say such deepfakes could be used to spread misinformation and even mislead the military.

MEXICO CITY (Reuters) — A global semiconductor chip shortage, which has hurt Mexico’s auto industry, could improve but still not be fully resolved by the end of the year, said the head of Intel Corp’s Mexico unit, Santiago Cardona.

Intel in late March said it will greatly expand its advanced chip manufacturing capacity with plans to spend as much as $20 billion to build two factories in Arizona and open its factories to outside customers.

WASHINGTON — The Department of Defense wants to see a prototype that can ensure spectrum is available whenever it’s needed for aerial combat training, according to an April 26 request from the National Spectrum Consortium.

The effort, focused specifically on the Operational Spectrum Comprehension, Analytics, and Response (OSCAR) project, is part of a larger portfolio included in the DoD’s office of research and engineering’s Spectrum Access Research & Development Program. That program hope to develop near real time spectrum management technologies that leverage machine learning and artificial intelligence to more efficiently and dynamically allocate spectrum assignments based on operational planning or on operational outcomes, a release said.

“I think of this set of projects as a toolset that’s really the beginning of starting to move toward pushing those fundamental technologies into more direct operational application,” Maren Leed, executive director of the National Spectrum Consortium, told C4ISRNET. It’s “starting to bridge from just sharing with commercial into capabilities that are going to enable warfighting much more directly.”

New Mars climate simulations point to ancient warming facilitated by high, cirrus-like clouds of water ice.

A team from the Universitat Politècnica de València (UPV), the Universitat de València (UV) and the Aiken Ophthalmic Clinic (through its Research Foundation) have designed and assessed in their laboratories a new groundbreaking implant, the only one in its kind, to correct presbyopia. As a result of the work of five years of research, they have created the first trifocal corneal inlay that is also fully transparent. Such an inlay would allow good eyesight to presbyopic people of objects located at several distances: far, intermediate (computer, mobile devices) and near. Their work has been published in Nature group’s Scientific Reports journal.

This inlay could be an alternative for those suffering from presbyopia who would rather not use glasses or contact lenses. Furthermore, it would be fully compatible with laser refractive surgery in myopic and hyperopic patients, as well as possible subsequent cataract interventions. We are suggesting something totally new that is also not incompatible with any other ocular therapy.

After four months of hand-wringing and a deep investigation into how a patient was diagnosed with cancer after getting uniQure’s hemophilia gene therapy, the FDA is allowing the trial to continue.

In December, the FDA put uniQure’s hemophilia B gene therapy on clinical hold in response to a case of hepatocellular carcinoma (a form of liver cancer) in a patient in the pivotal trial of etranacogene dezaparvovec.

UniQure and partner CSL Behring had already completed dosing in the affected studies, but the safety concern threatened the chances of the therapy in an indication targeted by Pfizer and Spark Therapeutics’ fidanacogene elaparvovec.

Saudi Arabia could save some $200 billion over the next ten years by switching from crude oil to natural gas and renewables for electricity production, Reuters reports, citing the Kingdom’s Finance Minister.

“Instead of buying fuel from the international markets at $60 and then selling it at $6 for Saudi utilities, or using some of our quota in OPEC to sell at $6, we’re going to actually displace at least 1 million barrels a day of oil equivalent in the next 10 years and replace it with gas and renewables,” Mohammed al-Jadaan said.

OPEC’s largest oil producer and world’s largest exporter of crude is on a desperate quest to reduce its dependence on oil revenues by diversifying its economy away from the flagship export stock. Earlier this year, Crown Prince Mohammed, who appears to be the de facto ruler of Saudi Arabia, announced yet another investment program with a view to this diversification that he said would “unlock new local investments valued at SAR 5 Trillion through the end of 2030.”